| 1 |
Golob JG, Hou G, Lee A, Grassberger H, Berinstein EM, Zataari ME, Khaykin V, Fry C, Berinstein JB, Nemzek J, Kamada N, Kao JY, Bishu S. IL-15 promotes inflammatory Th17 cells in the intestine.. [DOI: 10.1101/2023.03.11.532227] [Reference Citation Analysis]
|
| 2 |
Nakase H. Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy. Gut Liver 2023;17:49-57. [PMID: 36375793 DOI: 10.5009/gnl220017] [Reference Citation Analysis]
|
| 3 |
Kutschera M, Novacek G, Reinisch W, Högenauer C, Petritsch W, Haas T, Moschen A, Dejaco C. Tofacitinib in the treatment of ulcerative colitis : A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH). Wien Klin Wochenschr 2023;135:1-13. [PMID: 36454302 DOI: 10.1007/s00508-022-02110-2] [Reference Citation Analysis]
|
| 4 |
Komeda Y, Kono M, Kashida H, Tribonias G, Masaki S, Takada R, Nagai T, Hagiwara S, Nishida N, Takenaka M, Honjo H, Matsui S, Tsuji N, Kudo M. Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series. Ann Gastroenterol 2023;36:97-102. [PMID: 36593812 DOI: 10.20524/aog.2022.0768] [Reference Citation Analysis]
|
| 5 |
Sleiman J, Bassi M, Tsipotis E, Charabaty A. Medical Treatment Options for Ulcerative Colitis. Clin Colon Rectal Surg 2022;35:428-36. [PMID: 36591395 DOI: 10.1055/s-0042-1758048] [Reference Citation Analysis]
|
| 6 |
Lee KE, Faye AS, Vermeire S, Shen B. Perioperative Management of Ulcerative Colitis: A Systematic Review. Dis Colon Rectum 2022;65:S5-S19. [PMID: 36007165 DOI: 10.1097/DCR.0000000000002588] [Reference Citation Analysis]
|
| 7 |
Hans A, Battat R, Lukin DJ. Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. Curr Gastroenterol Rep 2022;24:157-70. [PMID: 36327029 DOI: 10.1007/s11894-022-00853-6] [Reference Citation Analysis]
|
| 8 |
Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2022;75:724-30. [PMID: 36122389 DOI: 10.1097/MPG.0000000000003616] [Reference Citation Analysis]
|
| 9 |
Dal Buono A, Gabbiadini R, Solitano V, Vespa E, Parigi TL, Repici A, Spinelli A, Armuzzi A. Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy. Clin Exp Gastroenterol 2022;15:121-8. [PMID: 35909812 DOI: 10.2147/CEG.S350193] [Reference Citation Analysis]
|
| 10 |
Girard C, Dirks M, Deslandres C. Tofacitinib to Treat Severe Acute Refractory Colitis in a Teenager: Case Report and Review of the Literature. JPGN Reports 2022;3:e241. [DOI: 10.1097/pg9.0000000000000241] [Reference Citation Analysis]
|
| 11 |
Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Rev Gastroenterol Hepatol 2022;16:737-52. [PMID: 35875997 DOI: 10.1080/17474124.2022.2106216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Sekhri S, Yarur AJ. Integrating new and emerging therapies into inflammatory bowel disease clinical practice. Curr Opin Gastroenterol 2022;38:328-36. [PMID: 35762692 DOI: 10.1097/MOG.0000000000000851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Gergely M, Prado E, Deepak P. Management of refractory inflammatory bowel disease. Curr Opin Gastroenterol 2022;38:347-57. [PMID: 35762694 DOI: 10.1097/MOG.0000000000000849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Berinstein JA, Atkuri NA, Berinstein EM, Sheehan JL, Johnson LA, Cohen-mekelburg SA, Jiang H, Wakim NI, Kidwell KM, Nahum-shani IB, Robert, Waljee AK, Higgins PD. Predictors of 90-Day Colectomy in Hospitalized Patients Receiving Infliximab for Acute Severe Ulcerative Colitis at a Tertiary Care Center.. [DOI: 10.1101/2022.05.16.22275155] [Reference Citation Analysis]
|
| 15 |
Peterson AR, Hilley P, De Cruz P. Combination Tofacitinib and Calcineurin Inhibitor in the Management of Treatment-Refractory Ulcerative Colitis May Be Effective, But Is It Necessary? Inflamm Bowel Dis 2022;28:e46. [PMID: 35045169 DOI: 10.1093/ibd/izab356] [Reference Citation Analysis]
|
| 16 |
Spiewak TA, Patel A. User's Guide to JAK Inhibitors in Inflammatory Bowel Disease. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Doherty G, Raine T, Panis Y. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. J Crohns Colitis 2022;16:179-89. [PMID: 34635910 DOI: 10.1093/ecco-jcc/jjab177] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 18 |
Katsanos KH, Armuzzi A. Effectiveness and safety of tofacitinib in ulcerative colitis: Done is better than perfect. Dig Liver Dis 2022;54:151-3. [PMID: 34953762 DOI: 10.1016/j.dld.2021.11.017] [Reference Citation Analysis]
|
| 19 |
Taxonera C, Carpio López D, Cabez Manas A, Hinojosa del Val JE. Clinical settings with tofacitinib in ulcerative colitis. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8660/2022] [Reference Citation Analysis]
|
| 20 |
Gaspard G, Hussaini S, Mandali D, Lieberamn E. Management of Inflammatory Bowel Disease. Clinical Approaches to Hospital Medicine 2022. [DOI: 10.1007/978-3-030-95164-1_2] [Reference Citation Analysis]
|
| 21 |
Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci 2021;22:11322. [PMID: 34768752 DOI: 10.3390/ijms222111322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
